MiR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 11, 2013, Pages 963-972

  Fang, Yue ^a   Shen, Huiling ^a   Li, Hao ^a   Cao, Yuan ^a   Qin, Rong ^a   Long, Lulu ^a   Zhu, Xiaolan ^a   Xie, Chanjuan ^a   Xu, Wenlin ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

Gastric cancer; MiR 106a; PTEN

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MICRORNA; MIRN106 MICRORNA, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PRIMER DNA; PROTEIN KINASE B; PTEN PROTEIN, HUMAN;

ARTICLE; ENZYMOLOGY; HUMAN; METABOLISM; MIR-106A; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; PTEN; STOMACH CANCER; STOMACH TUMOR; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

GASTRIC CANCER; MIR-106A; PTEN;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; DNA PRIMERS; HUMANS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; STOMACH NEOPLASMS; UP-REGULATION;

EID: 84888375831     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt106     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CACancer J Clin 2011, 61: 69-90.
2. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M and Scarffe JH, et al. Perioperative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N Engl J Med 2006, 355: 11-20.
3. Zhang CX, Huang S, Xu N, Fang JW, Shen P, Bao YH and Mou BH, et al. Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer. Anticancer Drugs 2007, 18: 581-586. (Pubitemid 46603629)
4. Liu H, Li N, Yao L, Jiang L, Bao G, Li J and Ma Q, et al. Prediction of doxorubicin sensitivity in gastric cancers based on a set of novel markers. Oncol Rep 2008, 20: 963-969.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116: 281-297.
6. Chaudhuri K and Chatterjee R. MicroRNA detection and target prediction: integration of computational and experimental approaches. DNA Cell Biol 2007, 26: 321-337. (Pubitemid 46799181)
7. Hebert C, Norris K, Scheper MA, Nikitakis N and Sauk JJ. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007, 6: 5.
8. Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T and Takahata S, et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009, 8: 1067-1074.
9. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y and Xiong W, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010, 285: 21496-21507.
10. Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C and Quan L, et al. MiR-106a is frequently up-regulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. Mol Carcinog 2012, 52: 634-646.
11. Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J and Hussey DJ. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011, 15: 429-438.
12. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT and Barbisin M, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005, 33: e179.
13. Xu L, Dai WQ, Xu XF, Wang F, He L and Guo CY. Effects of multipletarget anti-microRNA antisense oligodeoxyribonucleotides on proliferation and migration of gastric cancer cells. Asian Pac J Cancer Prev 2012, 13: 3203-3207.
14. Rabik CA and Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33: 9-23. (Pubitemid 46137553)
15. Zheng T, Wang J, Chen X and Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer 2010, 126: 2-10.
16. Hummel R, Hussey DJ and Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumor types. Eur J Cancer 2010, 46: 298-311.
17. Ma J, Dong C and Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010, 17: 523-531.
18. Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH and Abrams SL, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 2008, 27: 4086-4095. (Pubitemid 351931994)
19. Mellinghoff IK, Cloughesy TF and Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2007, 13: 378-381. (Pubitemid 46225339)
20. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J and Su F, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011, 286: 19127-19137.
21. Suh SS, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ and Kim T, et al. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci USA 2012, 109: 5316-5321.
22. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF and Pogribny IP. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008, 7: 2152-2159.
23. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J and Wenham RM, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008, 68: 425-433. (Pubitemid 351380068)
24. Dhar S, Hicks C and Levenson AS. Resveratrol and prostate cancer: promising role for microRNAs. Mol Nutr Food Res 2011, 55: 1219-1229.
25. Oki E, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K and Yamamoto M, et al. Genetic mutual relationship between PTEN and p53 in gastric cancer. Cancer Lett 2005, 227: 33-38.
26. Sun Y, St Clair DK, Fang F,Warren GW, Rangnekar VM, Crooks PA and St Clair WH. The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther 2007, 6: 2477-2486. (Pubitemid 47480413)
27. Jiang Z, Pore N, Cerniglia GJ, Mick R, Georgescu MM, Bernhard EJ and Hahn SM, et al. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 2007, 67: 4467-4473. (Pubitemid 46815097)
28. Dasari VR, Kaur K, Velpula KK, Gujrati M, Fassett D, Klopfenstein JD and Dinh DH, et al. Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS ONE 2010, 5: e10350.
29. Shih MC, Chen JY, Wu YC, Jan YH, Yang BM, Lu PJ and Cheng HC, et al. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene 2012, 31: 2389-2400.
30. Cenni V, Maraldi NM, Ruggeri A, Secchiero P, Del Coco R, De Pol A and Cocco L, et al. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. Int J Oncol 2004, 25: 1599-1608.
31. Inoue R, Matsuki NA, Jing G, Kanematsu T, Abe K and Hirata M. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol 2005, 146: 633-641. (Pubitemid 41573614)
32. Cantley LC and Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999, 96: 4240-4245. (Pubitemid 29190320)
33. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J and Gavrilova N, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 1999, 96: 6199-6204. (Pubitemid 29256643)
34. Maehama T, Okahara F and Kanaho Y. The tumour suppressor PTEN: involvement of a tumour suppressor candidate protein in PTEN turnover. Biochem Soc Trans 2004, 32: 343-347. (Pubitemid 38582124)